Osimertinib (Tagrisso)

From HemOnc.org - A Hematology Oncology Wiki
Jump to: navigation, search

General information

Class/mechanism: Mutant-selective EGFR tyrosine kinase inhibitor. Osimertinib preferentially binds irreversibly to certain mutant forms of the epidermal growth factor receptor (EGFR) (T790M, L858R, and exon 19 deletion) at approximately 9-times lower concentrations than wild-type. Two pharmacologically-active metabolites of osimertinib, AZ7550 and AZ5104, also emerge at about 10% the level of osimertinib. AZ7550 had similar potency to osimertinib. AZ5104 had about 8-times greater potency against exon 19 deletion and T790M mutants than osimertinib and 15-times greater potency against wild-type EGFR. Osimertinib also inhibits activity of HER2, HER3, HER4, ACK1, and BLK.[1][2][3]
Route: PO
Extravasation: n/a

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Diseases for which it is used

Patient drug information

History of changes in FDA indication

Also known as

  • Code name: AZD9291
  • Brand name: Tagrisso


  1. 1.0 1.1 1.2 1.3 1.4 Osimertinib (Tagrisso) package insert
  2. Osimertinib (Tagrisso) package insert (locally hosted backup)
  3. Tagrisso manufacturer's website
  4. Osimertinib (Tagrisso) patient drug information (Chemocare)
  5. Osimertinib (Tagrisso) patient drug information (UpToDate)